Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.
Marshall
Phillip B
PB
Mellman
Thomas A
TA
Nguyen
Shana Xuanlan C
SX
D000328:Adult; D000374:Aggression / Q000187:drug effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D001590:Benztropine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy*; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D009460:Neurologic Examination / Q000187:drug effects; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D001590:Benztropine; D000068180:Aripiprazole; D000077152:Olanzapine